Though, a current study describing the generation and preclinical characterization of a CLDN6-ADC for the treatment of ovarian and endometrial cancer using a patient-derived xenograft model showed reduced tumor volume specifically in CLDN6+ tumors (McDermott et al. 2022). Here, CLDN6 is linked to endometrial cancer.